Our key discovery

Brain Bispecific T cell Engager (BRiTE) hitchhiking drug delivery platform

A unique combination of novel T cell engager +
specifically manipulated polyclonal T cells

Benefit at a glance

In robust, preclinical studies and murine models, our BRiTE technology has shown:

  • Potential best-in-class efficacy
  • High specificity against tumor antigen-expressing glioma cells
  • Dose-response heterogeneic efficacy against multiple patient-derived malignant glioma cell lines
  • Non-toxicity
  • “Bystander” tumor cell lysis
  • Efficacy against heterogeneous tumors